Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke



Status:Recruiting
Conditions:Peripheral Vascular Disease, Cardiology, Neurology
Therapuetic Areas:Cardiology / Vascular Diseases, Neurology
Healthy:No
Age Range:18 - Any
Updated:3/14/2019
Start Date:September 2015
End Date:May 23, 2019

Use our guide to learn which trials are right for you!

A Phase 1b/2, Multi-Center, Double-Blind (Principal Investigators and Study Subjects Blinded, Sponsor Unblinded), Placebo-Controlled, Randomized, Single-Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

This is a Phase 1b/2, double-blind (Principal Investigators and study subjects blinded,
Sponsor unblinded), placebo-controlled, randomized, single-ascending dose, multi-center study
to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of
DS-1040b in subjects with Acute Ischemic Stroke (AIS).


Inclusion Criteria:

- Has a clinical diagnosis of acute ischemic stroke (including lacunar stroke/infarct)
supported by computed topography or magnetic resonance imaging to rule out alternative
cause for presenting symptoms

- Has onset of stroke symptoms within 4.5 to 12 hours before initiation of study drug
administration - for subjects with a stroke upon waking, time of symptom onset is the
last time the subject was known to be well

- Has a NIHSS score of ≥ 2 (for Cohorts 1-5) and ≥ 5 (for Cohort 6)

- Has Low dose heparin or low molecular weight heparin at a preventive dose are allowed
from 24 hours after treatment start completion and after confirmation of no
intracranial bleeding on the 24-hours repeat brain imaging.

- Is a Cohort 6 participant who is treated or anticipated to be treated with
intra-arterial therapy (IAT) for ischemic stroke at the time of randomization (for
enrollment in the IAT subgroup)

- Has given written informed consent to participate in the study prior to participating
in any study-related procedures - depending on country-specific practice, written
informed consent may be acceptable from legally authorized representative

- Has given a separate written informed consent for collecting a blood sample for
genotyping

Exclusion Criteria:

- Is a Cohort 1-5 participant who has been treated or is going to be treated with tissue
plasminogen activator (tPA) and/or endovascular thrombectomy during current stroke

- Is a Cohort 6 participant treated or anticipated to be treated with tPA during current
stroke

- Has evidence of intracranial hemorrhage on non-contrast computed tomography (CT/CAT)
scan or magnetic resonance imaging (MRI)

- Has symptoms of subarachnoid hemorrhage, even with normal imaging

- Has an Alberta Stroke Program Early CT Score (ASPECTS) <6

- Has prior non-traumatic intracranial hemorrhage (excluding microhemorrhages observed
in imaging)

- Has known arteriovenous malformation or aneurysm

- Has evidence of active bleeding

- Has platelet count less than 100,000

- Has International Normalized Ratio greater than 1.7

- Has used unfractionated heparin within 24 hours prior to treatment and has an elevated
partial thromboplastin time

- Has used a non-vitamin K antagonist oral anticoagulant such as dabigatran,
rivaroxaban, apixaban, or other factor Xa inhibitors within 24 hours before treatment

- Has used fondaparinux or low molecular weight heparin at an anticoagulation dose
within 24 hours prior to treatment

- Has anticipated use of an anticoagulation dose of heparin, or fondaparinux or low
molecular weight heparin, or nonvitamin K antagonist oral anticoagulant such as
dabigatran, rivaroxaban, apixaban, or other factor Xa inhibitors within 48 hours after
completion of study drug treatment (low dose heparin or low molecular weight heparin
at a preventive dose are allowed from 24 hours after treatment completion and after
confirmation of no intracranial bleeding on the 24 hours repeat brain imaging. In
Cohort 6, heparin treatment associated with IAT is allowed.)

- Has blood pressure > 185/110 mmHg, or requires aggressive medication to maintain blood
pressure below this limit (routine medical treatment including IV drug treatment is
allowed to lower the blood pressure below this limit)

- Has had intracranial surgery, clinically significant head trauma (in the opinion of
Principal Investigator), Alteplase treatment, or a previous stroke within 1 month

- Has had major surgery within 14 days

- Has had gastrointestinal or genitourinary bleeding in the last 21 days

- Has had a lumbar puncture (or epidural steroid injection) within 14 days

- Has had a preexisting disability classified by mRS > 2

- Has an estimated glomerular filtration rate < 60 mL/min/1.73 m^2

- Has baseline hemoglobin < 10.5 g/dL

- Has a positive pregnancy test

- Is currently participating in another investigational study or has participated in an
investigational drug study within 30 days or 5 half-lives of that investigational drug
prior to administration of the study drug

- Is an employee or an immediate family member of an employee of the Sponsor, the
Contract Research Organization (CRO), or the Site

- Has any other condition the investigator determines would preclude participation in
the study
We found this trial at
20
sites
500 University Dr
Hershey, Pennsylvania 17033
(717) 531-6955
Phone: 717-531-3828
Penn State Milton S. Hershey Medical Center Penn State Milton S. Hershey Medical Center, Penn...
?
mi
from
Hershey, PA
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Chattanooga, Tennessee 37403
Phone: 423-413-2413
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Phone: 312-942-8591
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1400 East Boulder Street
Colorado Springs, Colorado 80809
Phone: 719-365-2259
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Columbia, South Carolina 29203
Phone: 803-545-6078
?
mi
from
Columbia, SC
Click here to add this to my saved trials
Columbus, Ohio 43210
Phone: 614-685-7234
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Detroit, Michigan 48202
Phone: 313-916-9107
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Durham, North Carolina
Phone: 919-684-8969
?
mi
from
Durham, NC
Click here to add this to my saved trials
65 James Street
Edison, New Jersey 08820
Phone: 732-321-7950
?
mi
from
Edison, NJ
Click here to add this to my saved trials
Houston, Texas 77030
Phone: 713-441-7161
?
mi
from
Houston, TX
Click here to add this to my saved trials
Lexington, Kentucky 40536
Phone: 859-218-5443
?
mi
from
Lexington, KY
Click here to add this to my saved trials
10945 Le Conte Avenue
Los Angeles, California 90024
Phone: 310-794-0600
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
500 S Preston St
Louisville, Kentucky
(502) 852-5555
University of Louisville The University of Louisville is a state supported research university located in...
?
mi
from
Louisville, KY
Click here to add this to my saved trials
1700 Center Street
Mobile, Alabama 36604
Phone: 251-445-8292
?
mi
from
Mobile, AL
Click here to add this to my saved trials
1428 Madison Ave
New York, New York 10029
(212) 241-6500
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
?
mi
from
New York, NY
Click here to add this to my saved trials
Portland, Oregon 97239
Phone: 503-494-7223
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Sydney, New South Wales 2065
Phone: +61 299267111
?
mi
from
Sydney,
Click here to add this to my saved trials
1124 W Carson St # B4s
Torrance, California 90502
Phone: 310-222-7930
?
mi
from
Torrance, CA
Click here to add this to my saved trials